Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Ardelyx Inc (NQ: ARDX )

6.670 USD +0.010 (+0.15%)
Official Closing Price Updated: 5:57 PM EST, Mar 5, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Ardelyx Inc

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Knight Therapeutics Announces Canadian Commercial Launch of IBSRELA™ - New Innovative Treatment for Irritable Bowel Syndrome with Constipation
From GlobeNewswire News Releases
Ardelyx to Present at the 10th Annual SVB Leerink Global Healthcare Conference
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today... 
From PR Newswire
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Aileron Therapeutics (NASDAQ:ALRN) stock moved upwards by 33.25% to $1.8 during Friday's after-market session. This ... 
Tags General AZRX BNGO
From Benzinga
Thinking about buying stock in Capricor Therapeutics, Cardtronics, Clearside Biomedical, Ardelyx, or FuelCell Energy?
InvestorsObserver issues critical PriceWatch Alerts for CAPR, CATM, CLSD, ARDX, and FCEL. 
From PR Newswire
Benzinga's Top Upgrades, Downgrades For January 6, 2021
Upgrades For Regenxbio Inc (NASDAQ:RGNX), Raymond James upgraded the previous rating of Outperform to Strong Buy. For ... 
Tags Market News BZI/Ratings COR
From Benzinga
Analysts Expect LABU To Hit $150
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Top Buys by Directors: Mott's $1M Bet on ARDX
The directors of a company tend to have a unique inside view into the business, so when directors make major buys, investors are wise to take notice. Presumably the only reason a director of a company... 
Tags Stocks
From Market News Video
Noteworthy Thursday Option Activity: ARDX, IIPR, MGNX
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Ardelyx Inc (ARDX), where a total of 3,858 contracts have traded so far, representing... 
Tags Stocks
From Market News Video
72 Biggest Movers From Friday
Gainers AbCellera Biologics Inc. (NASDAQ: ABCL) shares jumped 194.5% to close at $58.90 after the company priced its IPO at $20 ... 
Tags Movers From Friday MKGI PCVX
From Benzinga
Notable Insider Buys Of The Past Week: Avis Budget, Biotech IPOs, And More
As the year winds down, plenty of insiders have purchased shares despite some market volatility and economic uncertainty. Here are some of the most noteworthy insider purchases that were reported in... 
Tags Stocks / Equities
From Blogs - TalkMarkets
Notable Insider Buys Of the Past Week: Avis Budget, Biotech IPOs And More
Insider buying can be an encouraging signal for potential investors when markets face uncertainty. This past week, some insiders ... 
Tags Multiplan Avnet Coty
From Benzinga
60 Stocks Moving In Friday's Mid-Day Session
Gainers TPG Pace Beneficial Finance Corp. (NYSE: TPGY) shares jumped 111.5% to $23.48 on a merger deal with EV charging company ... 
Tags XXII Mid/Day Movers JOUT
From Benzinga
Friday 12/11 Insider Buying Report: ARDX, BCAT
As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys. 
Tags Stocks
From Market News Video
Thinking about buying stock in Walt Disney, vTv Therapeutics, 22nd Century Group, Lexicon Pharmaceuticals, or Ardelyx?
InvestorsObserver issues critical PriceWatch Alerts for DIS, VTVT, XXII, LXRX, and ARDX. 
From PR Newswire
12 Healthcare Stocks Moving In Friday's Pre-Market Session
Gainers vTv Therapeutics (NASDAQ:VTVT) stock moved upwards by 120.09% to $4.82 during Friday's pre-market session. ... 
Tags Top Gainers Pre/Market Outlook IMMP
From Benzinga
Ardelyx to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today... 
From PR Newswire
Ardelyx to Present at the Jefferies Virtual London Healthcare Conference
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today... 
From PR Newswire
Ardelyx to Webcast Virtual Analyst Day
--Featuring a panel of distinguished guest speakers-- 
From PR Newswire
Analysts Expect 56% Upside For XBI
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Ardelyx Reports Third Quarter 2020 Financial Results and Business Highlights
Tenapanor NDA Accepted for Review by FDA; PDUFA Goal Date set for April 29, 2021 
From PR Newswire
Ardelyx and Kyowa Kirin Highlight New Data Supporting the Clinical Safety and Efficacy of First-In-Class, Phosphate Absorption Inhibitor Tenapanor at ASN's Kidney Week 2020
--Data presented across five posters continue to support the foundational role tenapanorcould play in the treatment of hyperphosphatemia-- 
From PR Newswire
Ardelyx Launches 'Can We Do Better?' Campaign at ASN's Kidney Week 2020
--Campaign highlights Ardelyx commitment to advance the science of phosphate absorption to address significant unmet needs in the current treatment of hyperphosphatemia-- 
From PR Newswire
Ardelyx Announces Data Supporting Efficacy and Safety of Tenapanor, a First-in-Class Phosphate Absorption Inhibitor, to be Presented at ASN's Kidney Week 2020
--Comprehensive datasets demonstrate tenapanor's ability to control serum phosphorous in patients with chronic kidney disease (CKD) on dialysis-- 
From PR Newswire
TUSA's Underlying Holdings Could Mean 10% Gain Potential
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
First Week of November 20th Options Trading For Ardelyx (ARDX)
Investors in Ardelyx Inc (ARDX) saw new options begin trading this week, for the November 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARDX options chain... 
Tags Stocks
From Market News Video
Ardelyx Announces FDA Acceptance for Filing of its New Drug Application of Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
NDA Supported by Data from Expansive Clinical Development Program Demonstrating Tenapanor's use as Foundational Therapy 
From PR Newswire
Ardelyx to Participate in Three Upcoming Investor Conferences in September
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that... 
From PR Newswire
How The Parts Add Up: LABU Targets $79
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Ardelyx Reports Second Quarter 2020 Financial Results and Recent Business Highlights
Submitted a New Drug Application to the U.S. Food and Drug Administration for the review of tenapanor as a first-in-class therapy to control serum phosphorus in adult patients with chronic kidney... 
From PR Newswire
Analysts See 45% Gains Ahead For XBI
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.